Eli Lilly and Company (LLY) — Stock analysis
USDCurrent price
1097,70 USD
-29,10 USD (-2.58%) today
Market signals
About Eli Lilly and Company
Eli Lilly is one of the world's largest pharmaceutical companies, historically focused on diabetes, oncology, immunology and neuroscience. Since 2022 the extraordinary success of Mounjaro/Zepbound (tirzepatide) — the type-2 diabetes and obesity drug that reshaped the GLP-1 category — has transformed the growth trajectory. The obesity + Alzheimer's (donanemab) pipeline is now the main valuation driver. Headquartered in Indianapolis, Indiana.
What does Eli Lilly do?▾
Eli Lilly is a pharmaceutical company focused on diabetes (Trulicity, Mounjaro), obesity (Zepbound), oncology (Verzenio), Alzheimer's (donanemab/Kisunla) and immunology. The diabetes/obesity segment is now over 50% of revenue.
Why has Eli Lilly grown so much since 2022?▾
Because of the success of tirzepatide, the active ingredient behind Mounjaro (type-2 diabetes) and Zepbound (obesity). These GLP-1 drugs have generated demand structurally above production capacity, with revenue growing from $7 billion (2022) to over $30 billion (2025-2026 projected).
Does Eli Lilly pay dividends?▾
Yes. It pays a quarterly dividend raised annually since 2014. Yield is typically 0.5-0.8% — low because the stock's rapid appreciation has diluted yield calculated on current price.
Analyse this stock with AI
Create a free account and get 2 credits to generate a complete analysis.
Create account · 2 free credits